Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by analysts at Rosenblatt Securities to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.
A number of other equities research analysts have also weighed in on the stock. Cantor Fitzgerald raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th. Benchmark raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st. Finally, BTIG Research raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, April 14th. Five equities research analysts have rated the stock with a strong buy rating, According to data from MarketBeat, the stock has an average rating of “Strong Buy”.
Get Our Latest Stock Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- A Deeper Look at Bid-Ask Spreads
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
